EPR监管周报:2026年11月16–20日——MHRA基因治疗定义修订、AdvanceGxP计划与FDA药品质量抽样检测及全球依赖披露计划
The EPR Regulatory Roundup: 16–20 November 2026
MHRA公布基因治疗药品定义修订咨询结果,拟推进立法以涵盖合成基因疗法和基因组编辑疗法。MHRA同日宣布AdvanceGxP计划,为个性化药物制造及机器人、自动化、AI等技术开发者提供早期监管与质量支持。FDA启动EAST药品质量抽样检测计划,并从零售药房和批发商取样评估产品鉴别、纯度和效价;另推出GRDP,初期适用于PEPFAR下部分暂定批准。
A weekly roundup of the latest regulatory updates affecting pharmaceutical development, manufacturing and commercialisation, from new guidance and quality standards to GMP requirements, legislative changes and significant medicine approvals.

Welcome to this week’s Regulatory Roundup, covering the latest regulatory updates from around the world. This week, we look at proposed changes to gene therapy medicinal product definitions, new MHRA support for advanced manufacturing, the FDA’s latest drug quality testing initiative and developments in international regulatory cooperation.
MHRA proposes changes to gene therapy definitions
19 November 2026 | UK | MHRA
The Medicines and Healthcare products Regulatory Agency (MHRA) has published the outcome of its consultation on proposed changes to the definition of gene therapy medicinal products (GTMPs) under the Human Medicines Regulations 2012. The proposals aim to modernise the definition to account for certain synthetic gene therapies and genome-editing treatments.
Advances in gene therapy have challenged the suitability of definitions established in 2007, with newer technologies not always fitting neatly within the existing advanced therapy medicinal product (ATMP) framework. The proposed updates aim to ensure these developments are appropriately captured while maintaining continuity with existing ATMP principles. The MHRA intends to proceed with the required legislation to implement the changes.
MHRA launches AdvanceGxP to support advanced manufacturing technologies
18 November 2026 | UK | MHRA
The MHRA has announced AdvanceGxP, a new initiative designed to provide developers of novel medicines technologies with earlier regulatory and quality support. The service will initially focus on technologies associated with personalised medicine manufacturing and the use of robotics, automation and artificial intelligence (AI).
Supported by funding from the Office for Life Sciences, the initiative will enable developers to address regulatory and quality questions earlier in the development process, helping to reduce the risk of avoidable redesign and delays. The MHRA will establish a specialist team to develop and test the service, with initial capacity expected to be limited while the approach is evaluated.
FDA launches new drug quality sampling and testing approach
18 November 2026 | US | FDA
The US Food and Drug Administration (FDA) has launched its Enhanced Approach for Sampling and Testing (EAST) initiative to monitor the quality of medicines available in the US. The programme combines modern screening techniques with traditional testing methods to expand the scope of therapeutic classes, manufacturers and geographical regions covered by the agency’s quality monitoring activities.
Under the initiative, the FDA will collect drug samples from retail pharmacies and wholesale distributors and assess factors including product identity, purity and potency. The results will help the agency identify potential quality issues faster, determine whether regulatory action is necessary and inform future inspections.
FDA launches Global Reliance Disclosure Programme
17 November 2026 | US | FDA
The FDA has launched its Global Reliance Disclosure Programme (GRDP), allowing companies to obtain minimally redacted copies of FDA approval packages, including detailed scientific and regulatory assessments, for sharing with regulatory authorities outside the US.
The programme is initially available for certain tentative approvals under the President’s Emergency Plan for AIDS Relief (PEPFAR), excluding tentatively approved abbreviated new drug application products. Applicants must request participation within 10 calendar days of approval and confirm that the documentation will support a marketing application submitted to a foreign regulator.
The FDA plans to expand the programme in January 2027 to include all novel drug applications and biologics licence applications, with a further pathway for already approved medicines and biologics planned for early 2027. The initiative aims to support international collaboration and reduce duplication in medicine assessments, potentially accelerating access to treatments in other markets.
来源:European Pharmaceutical Review · europeanpharmaceuticalreview.com